2022
Readmission rates and risk factors for readmission after transcatheter aortic valve replacement in patients with end-stage renal disease
Park DY, An S, Hanna JM, Wang SY, Cruz-Solbes AS, Kochar A, Lowenstern AM, Forrest JK, Ahmad Y, Cleman M, Al Damluji A, Nanna MG. Readmission rates and risk factors for readmission after transcatheter aortic valve replacement in patients with end-stage renal disease. PLOS ONE 2022, 17: e0276394. PMID: 36264931, PMCID: PMC9584363, DOI: 10.1371/journal.pone.0276394.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseTranscatheter aortic valve replacementLength of stayAortic valve replacementIndex hospitalizationHospital mortalityReadmission ratesValve replacementRenal diseaseLonger LOSNational Readmission DatabaseRisk of readmissionChronic pulmonary diseaseMultivariable logistic regressionCardiovascular causesCardiovascular readmissionCause readmissionHospital readmissionPulmonary diseaseHospital chargesPoor outcomeRisk factorsHospital costsReadmissionHigher odds
2013
Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation
Ahmad Y, Lip GY. Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation. Contributions To Nephrology 2013, 179: 81-91. PMID: 23652451, DOI: 10.1159/000346726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAtrial FibrillationBenzimidazolesBeta-AlanineClinical Trials as TopicComorbidityDabigatranDisease ManagementEmbolismFemaleFibrinolytic AgentsHemorrhageHumansHypertensionIntracranial EmbolismMaleMorpholinesPatient SelectionPyrazolesPyridonesRenal Insufficiency, ChronicRiskRisk FactorsRivaroxabanSeverity of Illness IndexStrokeThiophenesThrombophiliaWarfarinConceptsSevere renal impairmentAtrial fibrillationRisk factorsGeneral populationRenal impairmentRenal diseaseRenal patientsAbsence of AFLarge randomised control trialBenefits of warfarinNew oral anticoagulantsChronic kidney diseaseCohort of patientsRisk of strokeRandomised control trialEctopic vascular calcificationMajority of trialsUnique management challengesAF independentSystemic embolismOral anticoagulantsRenal insufficiencyStroke preventionThromboembolic riskStroke risk